BioRegenerative Sciences, Inc. Releases L-Ease a Stem Cell, Antioxidant-Based Eye Drop for Cataract

The L-Ease eye drops contain a proprietary blend of SRM and antioxidants proven to protect eye tissue against the formation of opacities.

San Diego, CA, July 26, 2011 --( Dr. Greg Maguire, Paul Franck, and Peter Friedman, founders of BioRegenerative Sciences, Inc., a privately owned stem cell therapeutics corporation headquartered in San Diego, CA, USA, announced today the release of L-Ease, a topically applied eye drop for helping to prevent the formation of cataracts. BioRegenerative Sciences' clinical studies of L-Ease demonstrated that the opacities associated with cataract formation were reduced with the daily use of L-Ease. According to Dr. Greg Maguire, CEO and Chief Scientific Officer of BRS, "BRS' L-Ease restores the biochemical properties of the liquid bathing the eye's lens to a healthy state so that the eye tissue is no longer in a state were cataracts can form." Peter Friedman, president of BRS, said that "L-Ease is an easily applied topical eye drop that replaces in the eye what was normally present in the youthful, healthy eye." Dr. Clevinger, Medical Director at BRS, also added, "L-Ease uses BRS's patented core technology, known as S2RM Technology(TM) where stem cell released molecules from multiple stem cell types are used to formulate the drops." Maguire and Friedman further stated that molecules comprising the S2RM Technology(TM) replace the multitude of molecules that have been lost in the cataract condition. Development at BRS' research laboratories for the last several years and recently completed clinical trials allowed for L-Ease to be released for sale in the US market in August 2011. BRS's L-Ease can be purchased online at: For more information, please email, or call customer service at 877.892.9991.

BioRegenerative Sciences, Inc.
Dr. Greg Maguire